Select year
Categories

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

Feb 27, 2024 | Financial | Corporate

Read more

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Feb 27, 2024 | Products

Read more

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Feb 21, 2024 | Financial | Corporate

Read more

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

Feb 15, 2024 | Corporate | Products

Read more

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Feb 01, 2024 | Corporate

Read more

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Jan 30, 2024 | Corporate

Read more

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Jan 18, 2024 | Corporate | Products

Read more

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

Jan 09, 2024 | Products

Read more

Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Jan 03, 2024 | Corporate

Read more